Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Shilpak ChatterjeeParamita ChakrabortyAnusara DaenthanasanmakSupinya IamsawatGabriela AndrejevaLibia A LuevanoMelissa WolfUday K BaligaCarsten KriegCraig C BeesonMeenal MehrotraElizabeth G HillJeffery C RathmellXue-Zhong YuAndrew S KraftShikhar MehrotraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
This study highlights the potential therapeutic significance of combinatorial strategies where ACT and inhibition of signaling kinase with checkpoint blockade could improve tumor control.